Key facts
- Superluminal Medicines’s last known valuation is $189.9M (Jan 2025).
- It has raised $157.7M across 3 recorded rounds; the latest was Early Stage VC (Series A) ($120.0M) in Jan 2025.
- Notable investors include Insight Partners (New York), Gaingels, RA Capital Management, Evolution VC Partners, Catalio Capital Management — 8 tracked in total.
- Superluminal Medicines has filed 3 Form Ds with the SEC since 2023, most recently Aug 2025 ($5.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Superluminal Medicines
Funding rounds
3 roundsAbout Superluminal Medicines
Developer of a generative biology medicine technology intended to accelerate new possibilities in drug discovery and development. The company creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning and proprietary big data infrastructure, enabling the pharmaceutical industry to accelerate drug discovery and increase the probability of success in small molecule drug development.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 29
- Website
- superluminalrx.com/
- Ownership
- Privately Held (backing)
Superluminal Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Superluminal Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Superluminal Medicines in its N-PORT filings yet. We sweep new filings monthly.